or Try an Advanced Search...

    Technical Analysis for ACHL - Achilles Therapeutics plc

    Grade Last Price % Change Price Change
    F 0.92 0.00% 0.00
    ACHL closed unchanged on Wednesday, May 15, 2024, on 5 percent of normal volume.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Up
    Historical ACHL trend table...
    Date Alert Name Type % Chg
    Outside Day Range Expansion 0.00%
    Wide Bands Range Expansion 0.00%
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Inside Day Range Contraction 0.00%
    Overbought Stochastic Strength 0.00%
    Evening Star Bearish 3.39%
    Upper Bollinger Band Walk Strength 3.39%
    Weak + Overbought Other 3.39%
    Older End-of-Day Signals for ACHL ...

       Recent Intraday Alerts

    Alert Time
    Down 3% about 22 hours ago
    Fell Below Previous Day's Low about 22 hours ago
    Down 2 % about 22 hours ago
    Down 1% about 22 hours ago
    Possible NR7 1 day ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ACHL Chart by TradingView
    Basic chart:

    Profile

    Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Clinical Medicine Solid Tumors Cancer Treatment Cancer Immunotherapy Melanoma Antineoplastic Drugs Orphan Drug Breakthrough Therapy Bladder Cancer Head And Neck Cancer Renal Cell Carcinoma Advanced Non Small Cell Lung Cancer Head And Neck Squamous Cell Carcinoma Immuno Oncology Biopharmaceutical Triple Negative Breast Cancer

    Is ACHL a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 5 Piper downgrades Achilles to neutral, cites latest data
    Apr 4 Achilles Therapeutics GAAP EPS of -$0.46 misses by $0.32
    Apr 4 Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
    Apr 4 Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
    Feb 9 Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?
    Feb 5 Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
    Jan 24 Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year?
    Dec 18 Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
    Nov 13 Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
    See more ACHL news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.76
    52 Week Low 0.74
    Average Volume 281,567
    200-Day Moving Average 0.94
    50-Day Moving Average 0.98
    20-Day Moving Average 0.83
    10-Day Moving Average 0.87
    Average True Range 0.06
    RSI (14) 55.16
    ADX 27.28
    +DI 19.78
    -DI 13.51
    Chandelier Exit (Long, 3 ATRs) 0.79
    Chandelier Exit (Short, 3 ATRs) 0.92
    Upper Bollinger Bands 0.95
    Lower Bollinger Band 0.70
    Percent B (%b) 0.87
    BandWidth 30.89
    MACD Line -0.01
    MACD Signal Line -0.03
    MACD Histogram 0.0269
    Fundamentals Value
    Market Cap 37.52 Million
    Num Shares 40.8 Million
    EPS -1.90
    Price-to-Earnings (P/E) Ratio -0.48
    Price-to-Sales 0.00
    Price-to-Book 0.25
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.98
    Resistance 3 (R3) 0.98 0.95 0.97
    Resistance 2 (R2) 0.95 0.94 0.95 0.97
    Resistance 1 (R1) 0.94 0.93 0.94 0.94 0.96
    Pivot Point 0.91 0.91 0.92 0.92 0.91
    Support 1 (S1) 0.90 0.90 0.91 0.90 0.88
    Support 2 (S2) 0.87 0.89 0.88 0.87
    Support 3 (S3) 0.86 0.87 0.87
    Support 4 (S4) 0.86